Comparison of Diagnostic Accuracy of 111In-Pentetreotide Spect and 68Ga-Dotatoc Pet: a Lesion-By-Lesion Analysis in Prrt-Patients

Sofie Van Binnebeek(KU Leuven), Christophe M. Deroose(KU Leuven), B Vanbilloen(KU Leuven), Kris Bogaerts(Hasselt University), Felix M. Mottaghy(College Board), Luc Mortelmans(KU Leuven), Karin Haustermans(Radboud University Nijmegen), Christelle Terwinghe(KU Leuven), Michel Koole(KU Leuven), Kristof Baete(KU Leuven), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Chris Verslype(Universitair Ziekenhuis Leuven), A. Verbruggen(KU Leuven), Paul M. Clément(Universitair Ziekenhuis Leuven)

Annals of Oncology

June 1, 2013

10.1093/annonc/mdt201.6

Cited by 1

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

|The Lancet|2010|7.3k

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

|New England Journal of Medicine|2013|6.6k

Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors

|New England Journal of Medicine|2017|3.2k

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

|The Lancet Oncology|2018|2.5k

Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

|New England Journal of Medicine|2019|2.2k